CDC has been advised that the U.S. manufacturer (Winthrop
Pharmaceuticals, New York) has resumed production of primaquine
phosphate, the antimalarial drug that decreases the risk for
relapses from Plasmodium vivax and P. ovale. Therefore, primaquine
will no longer be available from the CDC Drug Service.
Reported by: Malaria Br, Div of Parasitic Diseases, and Scientific
Resources Program, National Center for Infectious Diseases, CDC.
Disclaimer
All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.
